| 151 |
8473315 | Inhibitory properties of full-length and truncated recombinant tissue factor pathway inhibitor (TFPI). Evidence that the third Kunitz-type domain of TFPI is not essential for the inhibition of factor VIIa-tissue factor complexes on cell surfaces. | 1993 Apr 25 |
1 |
| 152 |
1346095 | Lipoprotein-associated coagulation inhibitor (LACI) is a cofactor for heparin: synergistic anticoagulant action between LACI and sulfated polysaccharides. | 1992 Jan 15 |
10 |
| 153 |
1420819 | The present status of tissue factor pathway inhibitor. | 1992 Aug |
3 |
| 154 |
1442261 | The interaction between LACI and heparin. | 1992 |
1 |
| 155 |
1658969 | Extrinsic pathway inhibitor (EPI) and the post-heparin anticoagulant effect in tissue thromboplastin induced coagulation. | 1991 |
1 |
| 156 |
1664252 | Simultaneous presence of tissue factor pathway inhibitor (TFPI) and low molecular weight heparin has a synergistic effect in different coagulation assays. | 1991 Oct |
3 |
| 157 |
1755003 | Anti-Xa clotting activities in different hepatic-triglyceride lipase preparations from post-heparin plasma. | 1991 Sep 1 |
3 |
| 158 |
1794748 | Extrinsic pathway inhibitor--the key to feedback control of blood coagulation initiated by tissue thromboplastin. | 1991 |
1 |
| 159 |
1794751 | Heparin requires both antithrombin and extrinsic pathway inhibitor for its anticoagulant effect in human blood. | 1991 |
1 |
| 160 |
1799658 | Tissue factor pathway inhibitor with high anticoagulant activity is increased in post-heparin plasma and in plasma from cancer patients. | 1991 Dec |
6 |
| 161 |
2070076 | Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples. | 1991 Jul 15 |
4 |
| 162 |
2211593 | Recombinant human extrinsic pathway inhibitor. Production, isolation, and characterization of its inhibitory activity on tissue factor-initiated coagulation reactions. | 1990 Oct 5 |
1 |